IS7629A - Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu - Google Patents

Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu

Info

Publication number
IS7629A
IS7629A IS7629A IS7629A IS7629A IS 7629 A IS7629 A IS 7629A IS 7629 A IS7629 A IS 7629A IS 7629 A IS7629 A IS 7629A IS 7629 A IS7629 A IS 7629A
Authority
IS
Iceland
Prior art keywords
exchangeable
diabetic
obesity agent
method useful
heterocyclic derivatives
Prior art date
Application number
IS7629A
Other languages
English (en)
Inventor
T. W. Cheng Peter
Chen Sean
Z. Ding Charles
F. Herpin Timothy
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS7629A publication Critical patent/IS7629A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS7629A 2002-07-09 2005-01-05 Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu IS7629A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39455302P 2002-07-09 2002-07-09
PCT/US2003/021331 WO2004004655A2 (en) 2002-07-09 2003-07-08 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (1)

Publication Number Publication Date
IS7629A true IS7629A (is) 2005-01-05

Family

ID=30115733

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7629A IS7629A (is) 2002-07-09 2005-01-05 Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu

Country Status (23)

Country Link
US (2) US6875782B2 (is)
EP (1) EP1531810B1 (is)
JP (1) JP4541883B2 (is)
KR (1) KR101120337B1 (is)
CN (1) CN1665500A (is)
AT (1) ATE543497T1 (is)
AU (1) AU2003248861B2 (is)
BR (1) BR0312503A (is)
CA (1) CA2490972C (is)
ES (1) ES2380319T3 (is)
GE (1) GEP20084475B (is)
HR (1) HRP20050001A2 (is)
IL (1) IL165809A (is)
IS (1) IS7629A (is)
MX (1) MXPA05000279A (is)
NO (1) NO329328B1 (is)
NZ (1) NZ537251A (is)
PL (1) PL375230A1 (is)
RS (1) RS20050002A (is)
RU (1) RU2325381C2 (is)
UA (1) UA79296C2 (is)
WO (1) WO2004004655A2 (is)
ZA (1) ZA200500029B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537336A (ja) * 2002-08-01 2005-12-08 ニューロサーチ、アクティーゼルスカブ 抗血管新生治療に応答する疾患の治療に有用な化合物
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861302A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861301B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861300B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7829552B2 (en) * 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
US20060058224A1 (en) * 2004-09-15 2006-03-16 Yancopoulos George D Methods of treating obesity with combination therapeutics
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006117743A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
FR2889191A1 (fr) * 2005-07-28 2007-02-02 Cerep Sa Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
CA2626441A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
BRPI0712802A2 (pt) * 2006-05-30 2012-10-23 Astrazeneca Ab composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
CA2651663A1 (en) * 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103694195B (zh) * 2013-09-18 2016-04-06 华东师范大学 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
EP3190103A1 (en) * 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686636B1 (en) 1993-12-28 2001-04-04 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
CN1066148C (zh) 1995-06-15 2001-05-23 明治制果株式会社 三环性苯并氮杂䓬化合物
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) * 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
JPH1067759A (ja) 1996-06-20 1998-03-10 Sankyo Co Ltd 除草性アゾール誘導体
JPH11263775A (ja) 1997-09-08 1999-09-28 Sankyo Co Ltd ヒドロキシアニリン誘導体
RU2198885C2 (ru) 1997-09-29 2003-02-20 Мейдзи Сейка Кайся Лтд. Производные трициклического триазолобензазепина, способы их получения, фармацевтическая композиция и способ лечения аллергических заболеваний, промежуточные соединения и способы их получения
US6506757B1 (en) 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
FR2778314B1 (fr) 1998-05-07 2002-06-14 Rhone Poulenc Agrochimie Composition fongicide synergique comprenant un compose analogue de la strobilurine
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
ATE260912T1 (de) * 1999-09-08 2004-03-15 Glaxo Group Ltd Oxazol ppar antagonisten
TWI260321B (en) * 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PL356487A1 (en) 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
KR101120337B1 (ko) 2012-02-29
ES2380319T3 (es) 2012-05-10
EP1531810A2 (en) 2005-05-25
CA2490972A1 (en) 2004-01-15
JP2006501187A (ja) 2006-01-12
NO20045529L (no) 2005-02-03
AU2003248861B2 (en) 2009-01-22
UA79296C2 (en) 2007-06-11
EP1531810A4 (en) 2008-05-28
RU2325381C2 (ru) 2008-05-27
RU2005103395A (ru) 2005-08-10
NO329328B1 (no) 2010-09-27
US20050119312A1 (en) 2005-06-02
WO2004004655A2 (en) 2004-01-15
WO2004004655A3 (en) 2004-10-14
CN1665500A (zh) 2005-09-07
HRP20050001A2 (en) 2005-08-31
GEP20084475B (en) 2008-09-10
US7507757B2 (en) 2009-03-24
NZ537251A (en) 2007-02-23
BR0312503A (pt) 2007-06-26
RS20050002A (sr) 2007-09-21
EP1531810B1 (en) 2012-02-01
MXPA05000279A (es) 2005-03-31
US6875782B2 (en) 2005-04-05
IL165809A (en) 2010-05-17
CA2490972C (en) 2012-05-29
ZA200500029B (en) 2006-06-28
PL375230A1 (en) 2005-11-28
JP4541883B2 (ja) 2010-09-08
US20040063762A1 (en) 2004-04-01
IL165809A0 (en) 2006-01-15
AU2003248861A1 (en) 2004-01-23
ATE543497T1 (de) 2012-02-15
KR20050025951A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
IS7629A (is) Skiptitengdar heterósýklískar afleiður, og aðferð, gagnlegar sem virk efni gegn sykursýki og offitu
WO2004004665A3 (en) Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
NO20000847D0 (no) Elastiske brønnsementsammensetninger og fremgangsmåter
HK10777456A1 (en) Sustained-release table composition of pramipexole
BR0317715A (pt) Composições e processos de uso de collajolie
DE60232456D1 (de) Härtbare zusammensetzung
IS7519A (is) 11-beta-hýdroxýstera vetnissviftir 1 hindrar nytsamlegir í meðferð við sykursýki, offitu og blóðfituröskun
DE60314124D1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
DK1524981T3 (da) Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
GB0114185D0 (en) Compounds
DE60214367D1 (de) Härtbare zusammensetzung
IS7060A (is) 2,5-díarýlpýrasín, 2,5-díarýlpýridín og 2,5-díarýlpýrimidín sem CRF1 viðtakabeinar
ITBO20020068A0 (it) Unita' per l'alimentazione di componenti ad una stazione di montaggiodi almeno un componente su un pannello di legno o simili
DE60322926D1 (de) Photopolymerisierbare zusammensetzung und verwendung davon
AU2003290735A8 (en) Inhibitors of monoamine uptake
DE60216645D1 (de) Antiulcus pflanzenzusammensetzung(en)
DK1483317T3 (da) Svidningsinhibitorsammensætning med lav gulning
ATE396170T1 (de) Monoamin-aufnahme-inhibitor
DE60206024D1 (de) Härtbare zusammensetzung
EA200800681A1 (ru) Применение киралаксила для защиты от фитопатогенов и соответствующие способы и композиции
DE50211891D1 (de) Härtbare cyanat-zusammensetzungen
ITMI20020624A1 (it) Composizioni ad attivita' biostimolante
NO20050769L (no) Fremgangsmate til a innfore en 1,2-dobbelbinding i 3-okso-4-azasteroidforbindelser
GB0211949D0 (en) Novel compounds compositions and processes
ATE347368T1 (de) Antiulcus pflanzenzusammensetzung(en)